Oxford BioTherapeutics, an international biotechnology company focused on the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, has appointed Dr Keith E Wilson as Chief Scientific Officer. He joins the company from AbbVie where he was Director, Biologics Technology and Global Leader for Antibody Drug Conjugates.
Wilson has more than 20 years’ experience of life sciences research and development, specialising in oncology and immunology.
Before AbbVie, he was Senior Director of Research at Facet Biotech, prior to which he was Director, Pipeline Strategy/Early Discovery and Computational Biology at PDL BioPharma. He also held positions of increasing seniority at EOS Biotechnology, where he began his industry career as a scientist.
